Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
26
10
2022
accepted:
16
01
2023
medline:
17
4
2023
pubmed:
7
2
2023
entrez:
6
2
2023
Statut:
ppublish
Résumé
The European Academy of Dermatology and Venereology (EADV) Task Forces (TFs) on Quality of Life (QoL) and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa (ARHS) do not recommend the use of any generic instrument as a single method of Health Related (HR) QoL assessment in rosacea, except when comparing quimp (quality of life impairment) in rosacea patients with that in other non-dermatologic skin diseases and/or healthy controls. The EADV TFs on QoL and Patient-Oriented Outcomes and ARHS recommend the use of the dermatology-specific HRQoL instrument the Dermatology Life Quality Index (DLQI) and the rosacea-specific HRQoL instrument RosaQoL in rosacea patients. The DLQI minimal clinically important difference may be used as a marker of clinical efficacy of the treatment and DLQI score banding of 0 or 1 corresponding to no effect on patients' HRQoL could be an important treatment goal. This information may be added to consensuses and guidelines for rosacea.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
954-964Informations de copyright
© 2023 European Academy of Dermatology and Venereology.
Références
Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatology Symp Proc. 2011;15:2-11.
Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69:S27-35.
Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient's quality of life. Am Heal Drug Benefits. 2013;6:348-54.
Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15:12-5.
Buhl T, Sulk M, Nowak P, Buddenkotte J, McDonald I, Aubert J, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol. 2015;135:2198-208.
Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:53-62.
Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26:659-67.
Gerber PA, Buhren BA, Steinhoff M, Homey B. Rosacea: the cytokine and chemokine network. J Investig Dermatol Symp Proc. 2011;15:40-7.
Meyer-Hoffert U, Schröder J-M. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc. 2011;15:16-23.
Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc. 2011;15:33-9.
Schaller M, Schöfer H, Homey B, Hofmann M, Gieler U, Lehmann P, et al. Rosacea management: update on general measures and topical treatment options. J Dtsch Dermatol Ges. 2016;14(suppl):17-27.
Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. Topical ivermectin 10 mg/g and oral doxycycline 40 mg modified-release: current evidence on the complementary use of anti-inflammatory rosacea treatments. Adv Ther. 2016;33:1481-501.
Pietschke K, Schaller M. Long-term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol. J Dermatolog Treat. 2018;29:310-3.
Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9:e1361574.
van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MMD, Charland L, Cochrane Skin Group. Interventions for rosacea. Cochrane Database Syst Rev. 2015;2015:CD003262.
Hofmann MA, Lehmann P. Physical modalities for the treatment of rosacea. J Dtsch Dermatol Ges. 2016;14(suppl):38-43.
Oliveira CMM, Almeida LMC, Bonamigo RR, Lima CWG, Bagatin E. Consensus on the therapeutic management of rosacea - Brazilian Society of Dermatology. An Bras Dermatol. 2020;95(Suppl 1):53-69.
Salleras M, Alegre M, Alonso-Usero V, Boixeda P, Domínguez-Silva J, Fernández-Herrera J, et al. Spanish consensus document on the treatment algorithm for rosacea. Actas Dermosifiliogr (Engl Ed). 2019;110:533-45.
Asai Y, Tan J, Baibergenova A, Barankin B, Cochrane CL, Humphrey S, et al. Canadian Clinical Practice Guidelines for Rosacea. J Cutan Med Surg. 2016;20:432-45.
Yang R, Liu C, Liu W, Luo J, Cheng S, Botulinum MX, et al. Alleviates persistent erythema and Flushing in patients with erythema telangiectasia rosacea. Dermatol Ther (Heidelb). 2022;12:2285-94.
Weissenbacher S, Merkl J, Hildebrandt B, Wollenberg A, Braeutigam M, Ring J, et al. Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial. Br J Dermatol. 2007;156:728-32.
Campos MA, Sousa AC, Varela P, Baptista A, Menezes N. Comparative effectiveness of purpuragenic 595 nm pulsed dye laser versus sequential emission of 595 nm pulsed dye laser and 1,064 nm Nd:YAG laser: a double-blind randomized controlled study. Acta Dermatovenerol Alp Pannonica Adriat. 2019;28:1-5.
Williamson T, Cheng WY, McCormick N, Vekeman F. Patient preferences and therapeutic satisfaction with topical agents for rosacea: a survey-based study. Am Health Drug Benefits. 2018;11:97-106.
Trumbore MW, Goldstein JA, Gurge RM. Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. J Drugs Dermatol. 2009;8:299-304.
Williamson T, Cameron J, McLeod K, Turner B, Quillen A, LaRose A, et al. Concerns and treatment satisfaction in patients being treated with Azelaic acid foam for rosacea. J Drugs Dermatol. 2019;18:381-6.
Schweinzer K, Kofler L, Spott C, Krug M, Schulz C, Schnabl SM, et al. Surgical treatment of rhinophyma: experience from a German cohort of 70 patients. Eur J Dermatol. 2017;27:281-5.
van der Linden MMD, van Ratingen AR, van Rappard DC, Nieuwenburg SA, Spuls PI. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety. Br J Dermatol. 2017;176:1465-74.
Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.
Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatolog Treat. 2020;31:168-74.
Webster G, Schaller M, Tan J, Jackson JM, Kerrouche N, Schäfer G. Defining treatment success in rosacea as ‘clear’ may provide multiple patient benefits: results of a pooled analysis. J Dermatolog Treat. 2017;28:469-74.
Schoelermann AM, Weber TM, Arrowitz C, Rizer RL, Qian K, Babcock M. Skin compatibility and efficacy of a cosmetic skin care regimen with licochalcone a and 4-t-butylcyclohexanol in patients with rosacea subtype I. J Eur Acad Dermatol Venereol. 2016;30(Suppl 1):21-7.
Aripova ML, Khardikova SA. Impact of opisthorchis invasion on the course of a skin process in patients with rosacea. Med Parazitol (Mosk). 2015;3:36-8.
Luger T, Peukert N, Rother M. A multicentre, randomized, placebo-controlled trial establishing the treatment effect of TDT 068, a topical formulation containing drug-free ultra-deformable phospholipid vesicles, on the primary features of erythematotelangiectatic rosacea. J Eur Acad Dermatol Venereol. 2015;29:283-90.
Tyring S, Solomon JA, Staedtler G, Lott JP, Nkulikiyinka R, Shakery K. Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial. Cutis. 2016;98:269-75.
Wienholtz NKF, Christensen CE, Haugaard JH, Zhang DG, Ashina M, Thyssen JP, et al. Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO). BMJ Open. 2020;10:e039445.
Bamford JT, Gessert CE, Haller IV, Kruger K, Johnson BP. Randomized, double-blind trial of 220 mg zinc sulfate twice daily in the treatment of rosacea. Int J Dermatol. 2012;51:459-62.
Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13:316-23.
Thomas CL, Kim B, Lam J, Richards S, See A, Kalouche S, et al. Objective severity does not capture the impact of rosacea, acne scarring and photoaging in patients seeking laser therapy. J Eur Acad Dermatol Venereol. 2017;31:361-6.
Sbidian E, Vicaut É, Chidiack H, Anselin E, Cribier B, Dréno B, et al. A randomized-controlled trial of Oral low-dose Isotretinoin for difficult-to-treat Papulopustular rosacea. J Invest Dermatol. 2016;136:1124-9.
Yang TT, Lan CE. Impacts of skin disorders associated with facial discoloration on quality of life: novel insights explaining discordance between life quality scores and willingness to pay. J Cosmet Dermatol. 2022;21:3053-8.
Bribeche MR, Fedotov VP, Gladichev VV, Pukhalskaya DM, Kolitcheva NL. Clinical and experimental assessment of the effects of a new topical treatment with praziquantel in the management of rosacea. Int J Dermatol. 2015;54:481-7.
Boehncke WH, Ochsendorf F, Paeslack I, Kaufmann R, Zollner TM. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol. 2002;12:577-80.
Wade M, Charest V, Ballardin B, Edge D, Nielsen MCE. Biophotonic therapy with fluorescent light energy decreases facial erythema, improves signs and symptoms of rosacea, and increases patient satisfaction: a Postmarket study. J Clin Aesthet Dermatol. 2021;14:16-21.
Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. J Drugs Dermatol. 2005;4:585-90.
Kini SP, Nicholson K, DeLong LK, Dannemann T, Estaris J, Foster J, et al. A pilot study in discrepancies in quality of life among three cutaneous types of rosacea. J Am Acad Dermatol. 2010;62:1069-71.
Kim J, Ahn JW, Ha S, Kwon SH, Lee O, Oh C. Clinical assessment of rosacea severity: oriental score vs. quantitative assessment method with imaging and biomedical tools. Skin Res Technol. 2017;23:186-93.
Weber TM, Ceilley RI, Buerger A, Kolbe L, Trookman NS, Rizer RL, et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalcone a. J Cosmet Dermatol. 2006;5:227-32.
Schaller M, Kemény L, Havlickova B, Jackson JM, Ambroziak M, Lynde C, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82:336-43.
Böhm D, Schwanitz P, Stock Gissendanner S, Schmid-Ott G, Schulz W. Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med. 2014;19:586-91.
Guertler A, Jøntvedt NM, Clanner-Engelshofen BM, Cappello C, Sager A, Reinholz M. Efficacy and safety results of micellar water, cream and serum for rosacea in comparison to a control group. J Cosmet Dermatol. 2020;19:2627-33.
Wang B, Deng YX, Yan S, Xie HF, Li J, Jian D. Efficacy of non-ablative fractional 1440-nm laser therapy for treatment of facial acne scars in patients with rosacea: a prospective, interventional study. Lasers Med Sci. 2021;36:649-55.
Langenbruch AK, Beket E, Augustin M. Quality of health care of rosacea in Germany from the patient's perspective: results of the national health care study Rosareal 2009. Dermatology. 2011;223:124-30.
Deng Q, Zhang SP, Deng YX, Liu FF, Shi W, Xie HF, et al. Willingness-to-pay and benefit-cost analysis of IPL for rosacea treatment: a cross-sectional study in China. Patient Prefer Adherence. 2020;14:1843-52.
Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O. The toxic edge-a novel treatment for refractory erythema and flushing of rosacea. Lasers Surg Med. 2019;51:325-31.
Taieb A, Passeron T, Ruzicka T, Berth-Jones J, Jacovella J, Huang MY, et al. Ivermectin cream improves health-related quality of life in patients with rosacea: data from a randomized trial. Br J Dermatol. 2016;175:1366-8.
Wu Y, Fu C, Zhang W, Li C, Zhang J. The dermatology life quality index (DLQI) and the hospital anxiety and depression (HADS) in Chinese rosacea patients. Psychol Health Med. 2018;23:369-74.
Peuvrel L, Quéreux G, Brocard A, Saint-Jean M, Vallet C, Mère A, et al. Evaluation of quality of life after a medical corrective make-up lesson in patients with various dermatoses. Dermatology. 2012;224:374-80.
Strand M, Bergqvist G, Griffith S, Bergqvist E. The effect of recurrent pulsed dye laser treatments in rosacea patients. J Cosmet Laser Ther. 2017;19:160-4.
Salamon M, Chodkiewicz J, Sysa-Jedrzejowska A, Wozniacka A. Quality of life in patients with rosacea. Przegl Lek. 2008;65:385-9.
Yang X, Ouyang Y, Deng Y, Xiao Y, Tang Y, Jian D, et al. Willingness-to-pay and benefit-cost analysis of Botulinum Toxin for the treatment of rosacea in China: findings from a web-based survey. Patient Prefer Adherence. 2021;15:1197-205.
Baldwin HE. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis. 2010;86(5 Suppl):26-36.
Tan SR, Tope WD. Pulsed dye laser treatment of rosacea improves erythema, symptomatology, and quality of life. J Am Acad Dermatol. 2004;51:592-9.
Tan J, Schöfer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M, et al. Prevalence of rosacea in the general population of Germany and Russia - the RISE study. J Eur Acad Dermatol Venereol. 2016;30:428-34.
Kubanov A, Gallyamova Y, Kravchenko A. Clinical picture, diagnosis and treatment of rosacea, complicated by Demodex mites. Dermatol Reports. 2019;11:7675.
Shim TN, Abdullah A. The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment. J Clin Aesthet Dermatol. 2013;6:30-2.
Chen M, Deng Z, Huang Y, Li J. Prevalence and risk factors of anxiety and depression in rosacea patients: a cross-sectional study in China. Front Psych. 2021;12:659171.
Schaller M, Dirschka T, Kemény L, Briantais P, Jacovella J. Superior efficacy with ivermectin 1% cream compared to metronidazole 075% cream contributes to a better quality of life in patients with severe papulopustular rosacea: a subanalysis of the randomized, investigator-blinded ATTRACT study. Dermatol Ther (Heidelb). 2016;6:427-36.
Li J, Li M, Chen Q, Fu J, Zhang M, Hao F. Quality of life among patients with rosacea: an investigation of patients in China using two structured questionnaires. J Eur Acad Dermatol Venereol. 2016;30:e98-9.
Yan F, Peng C. Analysis of the effect of DPL combined with clarithromycin in the therapy and improvement of rosacea. Contrast Media Mol Imaging. 2022;2022:9437697.
Fabbrocini G, Monteil CB, Carballido F. A cream containing the sap of oat plantlets and mandarin extract soothes the symptoms of rosacea and improves the quality of life of patients. J Eur Acad Dermatol Venereol. 2022;36(Suppl 8):3-11.
Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol. 2007;57:213-21.
Aktaş Karabay E, Karşıyakalı N, Karabay E. Evaluation of sexual functions in female rosacea patients: a prospective, case-control study. Int J Impot Res. 2020;32:628-34.
Aksoy B, Altaykan-Hapa A, Egemen D, Karagöz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163:719-25.
Huang Y, Yan S, Xie H, Wang B, Zhao Z, Huang Y, et al. Health related quality of life of rosacea patients in China assessed by dermatology life quality index and willingness to pay. Patient Prefer Adherence. 2022;16:659-70.
Harper J, Del Rosso JQ, Ferrusi IL. Cross-sectional survey of the burden of illness of rosacea by erythema severity. J Drugs Dermatol. 2018;17:150-8.
Chen Q, Tang Y, Shi X, Yang X, Shan S, Wang X, et al. Prevalence, clinical characteristics and health-related quality of life of rosacea in Chinese adolescents: a population-based study. J Eur Acad Dermatol Venereol. 2020;34:e737-9.
Beikert FC, Langenbruch AK, Radtke MA, Augustin M. Willingness to pay and quality of life in patients with rosacea. J Eur Acad Dermatol Venereol. 2013;27:734-8.
Menezes N, Moreira A, Mota G, Baptista A. Quality of life and rosacea: pulsed dye laser impact. J Cosmet Laser Ther. 2009;11:139-41.
Bulbul Baskan E, Akin BA. Evaluation of long-term efficacy, safety, and effect on life quality of pulsed dye laser in rosacea patients. J Cosmet Laser Ther. 2019;21:185-9.
Acar EM, Kaya Erdoğan H, Şaş S, Acer E. Evaluation of fibromyalgia syndrome in patients with rosacea. Arch Rheumatol. 2021;36:252-7.
Zierl S, Guertler A, Hildebrand JA, Clanner-Engelshofen BM, French LE, Reinholz M. A comprehensive epidemiological study of rosacea in Germany. Eur J Dermatol. 2021;31:744-51.
Baldwin HE, Harper J, Baradaran S, Patel V. Erythema of rosacea affects health-related quality of life: results of a survey conducted in collaboration with the National Rosacea Society. Dermatol Ther (Heidelb). 2019;9:725-34.
AlOtaibi HM, AlFurayh NA, AlNooh BM, Aljomah NA, Alqahtani SM. Quality of life assessment among patients suffering from different dermatological diseases. Saudi Med J. 2021;42:1195-200.
Tannus FC, Picosse FR, Soares JM, Bagatin E. Rosacea-specific quality of life questionnaire: translation, cultural adaptation and validation for Brazilian Portuguese. An Bras Dermatol. 2018;93:836-42.
Zeichner JA, Eichenfield LF, Feldman SR, Kasteler JS, Ferrusi IL. Quality of life in individuals with Erythematotelangiectatic and Papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2018;11:47-52.
Deng Y, Peng Q, Yang S, Jian D, Wang B, Huang Y, et al. The rosacea-specific quality-of-life instrument (RosQol): revision and validation among Chinese patients. PLoS One. 2018;13:e0192487.
Damiani G, Gironi LC, Grada A, Kridin K, Finelli R, Buja A, et al. COVID-19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): multi-center, real-life, telemedical, and observational prospective study. Dermatol Ther. 2021;34:e14848.
Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7:541-6.
Finlay AY, Sampogna F. What do scores mean? Informed interpretation and clinical judgement are needed. Br J Dermatol. 2018;179:1021-2.
Marron SE, Chernyshov PV, Tomas-Aragones L. Quality-of-life research in acne vulgaris: current status and future directions. Am J Clin Dermatol. 2019;20:527-38.
Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230:27-33.
Chernyshov PV. The evolution of quality of life assessment and use in dermatology. Dermatology. 2019;235:167-74.
Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18:6131.
Vestergaard C, Wollenberg A, Barbarot S, Christen-Zaech S, Deleuran M, Spuls P, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33:1644-59.
Medgyesi B, Dajnoki Z, Béke G, Gáspár K, Szabó IL, Janka EA, et al. Rosacea is characterized by a profoundly diminished skin barrier. J Invest Dermatol. 2020;140:1938-1950.e5.
Li G, Tang X, Zhang S, Deng Z, Wang B, Shi W, et al. Aging-conferred SIRT7 decline inhibits rosacea-like skin inflammation by modulating toll-like receptor 2-NF-κB signaling. J Invest Dermatol. 2022;142:2580-2590.e6.
Yoon SH, Hwang I, Lee E, Cho HJ, Ryu JH, Kim TG, et al. Antimicrobial peptide LL-37 drives rosacea-like skin inflammation in an NLRP3-dependent manner. J Invest Dermatol. 2021;141:2885-2894.e5.
Zhao Z, Liu T, Liang Y, Cui W, Li D, Zhang G, et al. N2-polarized neutrophils reduce inflammation in rosacea by regulating vascular factors and proliferation of CD4+ T cells. J Invest Dermatol. 2022;142:1835-1844.e2.
Chernyshov PV. Health-related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity. G Ital Dermatol Venereol. 2016;151:37-43.
Chernyshov PV, John SM, Tomas-Aragones L, Gonçalo M, Svensson A, Bewley A, et al. Quality of life measurement in occupational skin diseases. Position paper of the European academy of dermatology and venereology task forces on quality of life and patient oriented outcomes and occupational skin disease. J Eur Acad Dermatol Venereol. 2020;34:1924-31.
Chernyshov PV, Jiráková A, Hercogová J. Comparative study of the quality of life of children with atopic dermatitis from Ukraine and The Czech Republic. J Eur Acad Dermatol Venereol. 2011;25:1483-4.
Chernyshov PV, Ho RC, Monti F, Jirakova A, Velitchko SS, Hercogova J, et al. Gender differences in self-assessed health-related quality of life in children with atopic dermatitis. J Clin Aesthet Dermatol. 2016;9:19-24.
Chernyshov PV, Suru A, Gedeon I, Derevyanko LA, Tiplica GS, Salavastru CM. Epidermolysis bullosa-specific module of the infants and toddlers dermatology quality of life (InToDermQoL) questionnaire. J Eur Acad Dermatol Venereol. 2019;33:612-7.
Chernyshov PV, Boffa MJ, Corso R, Pustišek N, Marinovic B, Manolache L, et al. Creation and pilot test results of the dermatology-specific proxy instrument: the infants and toddlers dermatology quality of life. J Eur Acad Dermatol Venereol. 2018;32:2288-94.
Damiani G, Finelli R, Kridin K, Pacifico A, Buja A, Bragazzi NL, et al. Facial atopic dermatitis may be exacerbate by masks: insights from a multicenter, teledermatology, prospective study during COVID-19 pandemic. Ital J Dermatol Venerol. 2022;157:419-23.
Damiani G, Finelli R, Kridin K. Masks trigger facial seborrheic dermatitis and psoriasis: evidence from a multicenter, case-control study during COVID-19 pandemics. Ital J Dermatol Venerol. 2022;157:419-23.
Szepietowski JC, Matusiak Ł, Szepietowska M. Face mask-induced itch: a self-questionnaire study of 2,315 responders during the COVID-19 pandemic. Acta Derm Venereol. 2020;100:adv00152.
Chernyshov PV, Vozianova SV, Chubar OV. Quality of life of infants, toddlers and preschoolers with Seborrhoeic, allergic contact and atopic dermatitis before and during COVID-19 pandemic. Dermatol Ther (Heidelb). 2021;11:2017-26.
Chernyshov PV, Kolodzinska L. Prospective study on hand dermatitis in nurses and doctors during COVID-19 pandemic and its improvement by use of adopted recommendations of the European academy of dermatology and venereology task force on contact dermatitis. Dermatol Ther. 2020;33:e14396.
Cretu S, Dascalu M, Georgescu SR, Salavastru CM. Personal protective equipment use and face acne in health care providers during the COVID-19 pandemic in Romania: a new occupational acne type? J Eur Acad Dermatol Venereol. 2022;36:e18-20.
Balato A, Ayala F, Bruze M, Crepy MN, Gonçalo M, Johansen J, et al. European task force on contact dermatitis statement on coronavirus disease-19 (COVID-19) outbreak and the risk of adverse cutaneous reactions. J Eur Acad Dermatol Venereol. 2020;34:e353-4.
Chernyshov PV, Tomas-Aragones L, Augustin M, Svensson A, Bewley A, Poot F, et al. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2020;34:1666-71.
Finlay AY, Salek MS, Abeni D, Tomás-Aragonés L, van Cranenburgh OD, Evers AWM, et al. Why quality of life measurement is important in dermatology clinical practice: an expert-based opinion statement by the EADV task force on quality of life. J Eur Acad Dermatol Venereol. 2017;31:424-31.
Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Manolache L, Tzellos T, et al. Quality of life measurement in acne. Position paper of the European academy of dermatology and venereology task forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018;32:194-208.
Chernyshov PV, Tomas-Aragones L, Manolache L, Marron SE, Salek MS, Poot F, et al. Quality of life measurement in atopic dermatitis. Position paper of the European academy of dermatology and venereology (EADV) task force on quality of life. J Eur Acad Dermatol Venereol. 2017;31:576-93.
Chernyshov P, de Korte J, Tomas-Aragones L, Lewis-Jones S, EADV Quality of Life Task Force. EADV Taskforce's recommendations on measurement of health-related quality of life in paediatric dermatology. J Eur Acad Dermatol Venereol. 2015;29:2306-16.
Prinsen C, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MK, et al. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV taskforce on quality of life. J Eur Acad Dermatol Venereol. 2013;27:1195-203.
Sampogna F, Finlay AY, Salek SS, Chernyshov P, Dalgard FJ, Evers AWM, et al. Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology-specific instruments. J Eur Acad Dermatol Venereol. 2017;31:1429-39.
Chernyshov PV, Tomas-Aragones L, Manolache L, Svensson A, Marron SE, Evers AWM, et al. Which acne treatment has the best influence on health-related quality of life? Literature review by the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes. J Eur Acad Dermatol Venereol. 2018;32:1410-9.
Chernyshov PV, Lallas A, Tomas-Aragones L, Arenbergerova M, Samimi M, Manolache L, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European academy of dermatology and venereology task forces on quality of life and patient oriented outcomes, melanoma and non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2019;33:816-27.
Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European academy of dermatology and venereology task forces on quality of life and patient-oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33:1633-43.
Chernyshov PV, Linder MD, Pustišek N, Manolache L, Szepietowski JC, Tomas-Aragones L, et al. Quimp (quality of life impairment): an addition to the quality of life lexicon. J Eur Acad Dermatol Venereol. 2018;32:e181-2.
Finlay AY, Chernyshov PV, Tomas Aragones L, Bewley A, Svensson A, Manolache L, et al. Methods to improve quality of life, beyond medicines. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes. J Eur Acad Dermatol Venereol. 2021;35:318-28.
Chernyshov PV, Evers AWM, Bewley A, Tomas-Aragones L, Marron SE, Manolache L, et al. Quality of life assessment in core outcome sets: a position statement of the EADV task force on quality of life and patient oriented outcomes. J Eur Acad Dermatol Venereol. 2022;36:20-3.
Chernyshov PV, Tomas-Aragones L, Finlay AY, Manolache L, Marron SE, Sampogna F, et al. Quality of life measurement in alopecia areata. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes. J Eur Acad Dermatol Venereol. 2021;35:1614-21.
Chernyshov PV, Tomas-Aragones L, Manolache L, Pustisek N, Salavastru CM, Marron SE, et al. Quality of life measurement in vitiligo. Position statement of the European academy of dermatology and venereology task force on quality of life and patient oriented outcomes with external experts. J Eur Acad Dermatol Venereol. 2023;37:21-31.